Changes of hemoglobin levels after chemotherapy in patients with ovarian cancer and influence of anemia on prognosis
10.3760/cma.j.issn.1008-1372.2019.06.017
- VernacularTitle:卵巢恶性肿瘤化疗前后血红蛋白水平的变化及贫血对预后的影响
- Author:
Dingyu XU
1
;
Xiguang MAO
Author Information
1. 西南医科大学附属第一医院妇产科
- Keywords:
Ovarian neoplasms;
Antineoplastic combined chemotherapy protocols;
Hemoglobinometry;
Anemia
- From:
Journal of Chinese Physician
2019;21(6):876-879,884
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the changes of hemoglobin levels in patients with ovarian cancer after chemotherapy and the influence of anemia on the prognosis of patients.Methods A total of 73 patients with ovarian cancer were selected.SPSS 25.0 statistical software was used to analyze the changes of hemoglobin levels after chemotherapy.According to the hemoglobin content before chemotherapy,the patients were divided into anemia group (Hb ＞ 110 g/L) and non-anemia group (Hb ＜ 110 g/L).Log Rand was used to compare the difference of survival time between the two groups.COX model was used to analyze the related factors affecting the prognosis of ovarian malignant tumors.Results The hemoglobin content before and after six chemotherapy cycles were (108.24 ± 18.09) g/L and (100.17 ±21.06) g/L respectively,with significant difference (P =0.021).The incidence of anemia and the degree of anemia gradually increased.The rate of anemia after six cycles of chemotherapy was higher than before chemotherapy,with significant difference (P =0.027).Survival analysis showed that progression free survival (PFS) was significantly lower in the anemic group than in the non-anemic group (P =0.01).COX regression analysis showed that anemia,postoperative residual lesion size,and surgical clinical staging were independent factors affecting the prognosis of patients with ovarian malignant tumors.Conclusions Chemotherapy reduces the hemoglobin content in patients with ovarian malignant tumors and aggravates anemia.Anemia affects the survival rate of patients with ovarian malignant tumors and is an independent factor affecting the prognosis of patients.
